Skip to main content
. 2017 Aug 3;145:96–102. doi: 10.1016/j.antiviral.2017.07.022

Fig. 1.

Fig. 1

Antiviral effects of U18666A on FCoV-I KU2 and FCoV-II 79-1146. (A) Cytotoxic effects of U18666A in fcwf-4 cells. The black circles indicate treatment with U18666A, and the white circles indicate treatment with the solvent (water). Data represent four independent experiments. (B) U18666A induced accumulation of intracellular cholesterol. The cellular cholesterol content of cells was evaluated using a filipin-cholesterol stain. (C) Quantification of cellular cholesterol in fcwf-4 cells. The results are shown as mean ± SE. Data represent four independent experiments. **, p < 0.01 vs. solvent control. (D) Plaque reduction assay of FCoV in fcwf-4 cells treated with U18666A. (E) Inhibition of FCoV infection by U18666A in fcwf-4 cells. The results are shown as mean ± SE. Data represent four independent experiments. **, p < 0.01 vs. type I FCoV KU2. (F) Effects of U18666A on the viral protein. FCoV N protein was evaluated with IFA.